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L-DOPA is the most commonly prescribed drug for the treatment of Parkinson’s disease. Here, Moor et al.
(2011) report that phenylalanyl-tRNA synthetase catalyzes the misacylation of tRNAPhe by L-DOPA, suggest-
ing that it may contribute to the elevated levels of L-DOPA-containing proteins found in patients treated with
this drug.Aminoacyl-tRNA synthetases catalyze
the attachment of amino acids to their
cognate tRNA using a two-step mecha-
nism in which the amino acid is first acti-
vated by ATP, forming an enzyme-bound
aminoacyl-adenylate intermediate, then
transferred to tRNA to form the amino-
acyl-tRNA product. As misacylation of
tRNA results in the incorrect amino
acid being incorporated during protein
synthesis, aminoacyl-tRNA synthetases
must be highly specific, with error rates
of less than 3 3 104 misacylations/turn-
over. For some aminoacyl-tRNA synthe-
tases, discrimination by the active site is
not sufficient and an editing mechanism
is used to hydrolyze either the non-
cognate aminoacyl-adenylate interme-
diate (pre-transfer editing) or non-cognateFigure 1. Routes to incorporating L-DOPA into proteins
Four pathways for the incorporation of L-DOPA into proteins are shown. Three
of the pathways have previously been identified, while the fourth pathway—
misacylation of tRNAPhe by L-DOPA (shown in red)—is described by Moor
et al. (2011) in this issue of Chemistry & Biology.aminoacyl-tRNA product
(post-transfer editing). Phe-
nylalanyl-tRNA synthetases
present an interesting case,
the bacterial, archaeal, and
eukaryotic cytoplasmic
enzymes are (ab)2 heterote-
tramers with the active site
located in the a-subunit and
a post-transfer editing site lo-
cated in the b-subunit (Roy
et al., 2004). In contrast, the
mitochondrial and chloro-
plast phenylalanyl-tRNA syn-
thetases are monomeric
enzymes that lack editing
activity (Roy et al., 2005). The
ability of the active site to
discriminate between phenyl-
alanine and tyrosine is 15-
fold higher in mitochondrial
phenylalanyl-tRNA synthe-
tase than it is in cytoplasmic
phenylalanyl-tRNA synthe-
tase, reflecting both the lackof an editing domain in the mitochondrial
isozyme and a lower phenylalanine:tyro-
sine ratio in the mitochondria (Reynolds
et al., 2011). Although misacylation of
tRNAPhe by L-tyrosine is minimal, Safro
and colleagues have found that both cyto-
plasmic and mitochondrial phenylalanyl-
tRNA synthetases are relatively efficient
at catalyzing the misacylation of tRNAPhe
by m-tyrosine (3-hydroxyphenylalanine)
(Klipcan et al., 2009). In this issue, Moor
et al. (2011) have solved the structures of
the Thermus thermophilus and human
mitochondrial phenylalanyl-tRNA synthe-
tases bound to L-DOPA (L-3,4-dihydroxy-
phenylalanine) and show that the
T. thermophilus, human cytoplasmic and
human mitochondrial phenylalanyl-tRNA
synthetases all catalyze the misacylationChemistry & Biology 18, October 28, 2011 ªof tRNAPhe by L-DOPA. Both the
T. thermophilus and human cytoplasmic
phenylalanyl-tRNA synthetases also cata-
lyze the hydrolysis of misacylated L-
DOPA-tRNAPhe, presumably via their edit-
ing domains. Although the efficiency of
tRNAPhe misacylation by L-DOPA is less
than that for m-tyrosine, it is comparable
to the tyrosyl-tRNA synthetase catalyzed
misacylation of tRNATyr by L-DOPA, sug-
gesting that misacylation of tRNAPhe may
play a role in the incorporation of L-
DOPA into proteins.
L-DOPA is the immediate biosynthetic
precursor of the neurotransmitter dopa-
mine and, unlike dopamine, is able to
cross the blood-brain barrier. Co-admin-
istration of L-DOPA with a peripheral
DOPA decarboxylase inhibitor (e.g., car-2011 Elsevibidopa) is used to treat Par-
kinson’s disease and dopa-
mine-responsive dystonia.
L-DOPA has also been found
to reduce transition state
metals, resulting in oxidative
damage to proteins, DNA,
and other biomolecules
(Rodgers and Dean, 2000).
Oxidation of proteins contain-
ing L-DOPA leads to their
aggregation and has been
postulated to play a role in
atherosclerosis, cataract for-
mation, Alzheimer’s disease,
and Parkinson’s disease (Fu
et al., 1998; Molna´r et al.,
2005; Rodgers et al., 2006).
Incorporation of L-DOPA
into proteins can occur by
oxidation of tyrosine resi-
dues, catalytic conversion of
tyrosine to L-DOPA by ty-
rosinase, or misacylation of
tRNATyr (Rodgers and Dean,er Ltd All rights reserved 1201
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Previews2000; Rodgers and Shiozawa, 2008). By
demonstrating that phenylalanyl-tRNA
synthetases can misacylate tRNAPhe
with L-DOPA, Moor et al. (2011) provide
a fourth pathway for incorporating
L-DOPA into proteins (Figure 1). This
new pathway may be particularly relevant
to proteins synthesized by the mitochon-
dria, given the inability of the mitochon-
drial phenylalanyl-tRNA synthetase to
hydrolyze misacylated tRNAPhe.
Incorporation of L-DOPA through misa-
cylation of tRNAPhe is distinct from the
other known mechanisms for incorpo-
rating L-DOPA into proteins, as it replaces
a phenylalanine residue, whereas in the
other three mechanisms L-DOPA re-
places tyrosine. As a result, it should be
possible to quantify the extent to which
misacylation of tRNAPhe results in the
incorporation of L-DOPA into proteins
in vivo. Furthermore, since the efficiency
of tRNAmisacylation by L-DOPA appears1202 Chemistry & Biology 18, October 28, 20to be similar for the phenylalanyl- and
tyrosyl-tRNA synthetases, misincorpora-
tion of L-DOPA in place of phenylalanine
may also provide an estimate for the
frequency with which L-DOPA incorpora-
tion is due to misacylation of tRNATyr.
Given that L-DOPA is currently the most
commonly prescribed drug for Parkin-
son’s disease, it is imperative to deter-
mine the extent to which tRNA mis-
acylation is responsible for the elevated
levels of L-DOPA-containing proteins
found in patients treated with this drug
(Rodgers et al., 2006). The article by
Moor et al. (2011) in this issue of
Chemistry & Biology provides a way to
address this question.REFERENCES
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Photoactivatable fluorescent proteins are now widely used for cell and protein tracking and super-resolution
optical imaging. In this issue, Adam et al. (2011) report a general approach to introduce photochromism into
green-to-red photoconvertible proteins and describe newphotoactivatable protein with a complex four-state
flasher-like behavior and advanced characteristics.Green fluorescent protein (GFP) from
jellyfish Aequorea victoria and its nu-
merous mutants and homologs from di-
verse marine creatures possess a unique
type of posttranslational modifications—
a chromophore group formed via self-
catalyzed reactions from its own internal
amino acids (Chudakov et al., 2010). As
a result, GFP-like fluorescent proteins
(FPs) become fluorescent by themselves,
with no help of external enzymes or co-
factors except molecular oxygen. This
extraordinary ability makes it possible to
use FPs as fully genetically encoded
labels to mark specific cells, cell organ-
elles, and proteins and monitor processin live systems. Nowadays, they are an
indispensable toolkit in experimental
biology, which is used in thousands of
studies each year.
A particularly interesting and useful
group of FPs is photoactivatable FPs
(PAFPs) capable of drastically increasing
their fluorescence in a specific spectral
region in response to illuminationwith light
of specific wavelength and intensity (Chu-
dakov et al., 2010). There are two main
types of such proteins—irreversible and
reversible PAFPs. Proteins of the first
type photoconvert once from one state
to another due to irreversible photochem-
ical reactions of the chromophore (e.g.,extension of its conjugated p-system)
and/or surrounding amino acids (e.g.,
decarboxylation of a Glu residue) (Mizuno
et al., 2003; Chudakov et al., 2010). PAFPs
of the second type canbephotoconverted
multiple times due to cis-trans isomeri-
zation of the chromophore and/or re-
versible reactions such as protonation-
deprotonation and hydration-dehydration
(Chudakov et al., 2003, 2010; Brakemann
et al., 2011).
One of the first irreversible PAFPs
was green-to-red photoconvertible FPs
called Kaede (after the Japanese word
for maple leaf) (Ando et al., 2002). This
green FP becomes red after illumination
